Panitumumab - Biologic Drug Details

Summary for panitumumab

Tradenames:	1
High Confidence Patents:	2
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for panitumumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for panitumumab

Recent Clinical Trials for panitumumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
MapKure, LLC	Phase 1
ECOG-ACRIN Cancer Research Group	Phase 3
Vanderbilt-Ingram Cancer Center	Phase 1

See all panitumumab clinical trials

Recent Litigation for panitumumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd.	2023-10-20
Sorrento Therapeutics, Inc. and Official Committee of Unsecured Creditors	2023-02-13
Janssen Biotech, Inc. v. Amgen Inc.	2022-11-29

See all panitumumab litigation

PTAB Litigation

Petitioner	Date
GEMoaB Monoclonals GmbH et al.	2019-12-20
	2018-03-20
Forty Seven, Inc.	2018-01-08

See all panitumumab litigation

Pharmacology for panitumumab

Mechanism of Action	HER1 Antagonists
Established Pharmacologic Class	Epidermal Growth Factor Receptor Antagonist
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for panitumumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for panitumumab Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	6,235,883	2039-02-26	Company disclosures
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	7,807,798	2017-05-05	Company disclosures

3) Low Certainty: US Patents for panitumumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,016,338	2033-03-11	Patent claims search
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,016,440	2030-04-21	Patent claims search
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,022,451	2039-02-26	Patent claims search

International Patents for panitumumab

Country	Patent Number	Estimated Expiration
Germany	122008000009
Cyprus	2008003
Japan	2001523973

Supplementary Protection Certificates for panitumumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C 2008 003	Romania		PRODUCT NAME: PANITUMUMAB; NATIONAL AUTHORISATION NUMBER: RO EU/1/07/423/001, RO EU/1/07/423/002, RO EU/1/07/423/003; DATE OF NATIONAL AUTHORISATION: 20071203; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/423/001, EU/1/07/423/002, EU/1/07/423/003; DATE OF FIRST AUTHORISATION IN EEA: 20071203
122008000030	Germany		PRODUCT NAME: PANITUMUMAB MIT WENIGSTENS EINEM WIRKSTOFF AUSGEWAEHLT AUS IRINOTECAN, CISPLATIN, 5-FLUOROURACIL, GEMCITABIN, PACLITAXEL UND CARBOPLATIN; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071203
122008000009	Germany		PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071203